Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) shares fell 0.2% during mid-day trading on Thursday . The stock traded as low as $6.24 and last traded at $6.24. Approximately 400 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 10,816 shares. The stock had previously closed at $6.25.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Idorsia in a research report on Monday, August 3rd. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.
Get Our Latest Report on IDRSF
Idorsia Stock Performance
About Idorsia
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
See Also
- Five stocks we like better than Idorsia
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
